Lawrence Neil Richard, Arshad Muhammad Fahad, Pofi Riccardo, Ashby Sean, Dawson Jeremy, Tomlinson Jeremy W, Newell-Price John, Ross Richard J, Elder Charlotte J, Debono Miguel
Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield S10 2TN, UK.
Paediatric Endocrinology Department, Sheffield Children's NHS Foundation Trust, Sheffield S10 2TH, UK.
J Endocr Soc. 2023 Oct 7;7(12):bvad127. doi: 10.1210/jendso/bvad127. eCollection 2023 Nov 2.
The adrenocorticotropin hormone stimulation test (AST) is used to diagnose adrenal insufficiency, and is often repeated in patients when monitoring recovery of the hypothalamo-pituitary-adrenal axis.
To develop and validate a prediction model that uses previous AST results with new baseline cortisol to predict the result of a new AST.
This was a retrospective, longitudinal cohort study in patients who had undergone at least 2 ASTs, using polynomial regression with backwards variable selection, at a Tertiary UK adult endocrinology center. Model was developed from 258 paired ASTs over 5 years in 175 adults (mean age 52.4 years, SD 16.4), then validated on data from 111 patients over 1 year (51.8, 17.5) from the same center, data collected after model development. Candidate prediction variables included previous test baseline adrenocorticotropin hormone (ACTH), previous test baseline and 30-minute cortisol, days between tests, and new baseline ACTH and cortisol used with calculated cortisol/ACTH ratios to assess 8 candidate predictors. The main outcome measure was a new test cortisol measured 30 minutes after Synacthen administration.
Using 258 sequential ASTs from 175 patients for model development and 111 patient tests for model validation, previous baseline cortisol, previous 30-minute cortisol and new baseline cortisol were superior at predicting new 30-minute cortisol ( = 0.71 [0.49-0.93], area under the curve [AUC] = 0.97 [0.94-1.0]) than new baseline cortisol alone ( = 0.53 [0.22-0.84], AUC = 0.88 [0.81-0.95]).
Results of a previous AST can be objectively combined with new early-morning cortisol to predict the results of a new AST better than new early-morning cortisol alone. An online calculator is available at https://endocrinology.shinyapps.io/sheffield_sst_calculator/ for external validation.
促肾上腺皮质激素刺激试验(AST)用于诊断肾上腺功能不全,并且在监测下丘脑 - 垂体 - 肾上腺轴恢复情况时,患者常需重复进行该试验。
开发并验证一种预测模型,该模型利用既往AST结果及新的基础皮质醇水平来预测新的AST结果。
这是一项在英国一家三级成人内分泌中心进行的回顾性纵向队列研究,研究对象为至少接受过2次AST的患者,采用带有向后变量选择的多项式回归分析。模型基于175名成年人(平均年龄52.4岁,标准差16.4)在5年期间的258对AST数据构建而成,然后使用来自同一中心111名患者在1年期间(平均年龄51.8岁,标准差17.5)的数据进行验证,这些数据是在模型构建之后收集的。候选预测变量包括既往试验的基础促肾上腺皮质激素(ACTH)、既往试验的基础及30分钟时的皮质醇水平、两次试验之间的天数,以及新的基础ACTH和皮质醇,并结合计算的皮质醇/ACTH比值来评估8个候选预测指标。主要观察指标为注射合成促肾上腺皮质激素30分钟后测得的新试验皮质醇水平。
利用175名患者的258次连续AST数据进行模型构建,并使用111名患者的试验数据进行模型验证,结果显示,既往基础皮质醇、既往30分钟皮质醇及新的基础皮质醇在预测新的30分钟皮质醇水平方面优于单独使用新的基础皮质醇(r = 0.71 [0.49 - 0.93],曲线下面积[AUC] = 0.97 [0.94 - 1.0]),单独使用新的基础皮质醇时r = 0.53 [0.22 - 0.84],AUC = 0.88 [0.81 - 0.95])。
与单独使用新的清晨皮质醇相比,将既往AST结果与新的清晨皮质醇进行客观结合,能更好地预测新的AST结果。可通过https://endocrinology.shinyapps.io/sheffield_sst_calculator/获取在线计算器用于外部验证。